A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Eli Lilly and Company
ClinicalTrials ID:NCT07218341
This study assesses the long-term safety of pirtobrutinib in participants with CLL/SLL who completed the J2N-MC-JZNN/LOXO-BTK-20020 trial. Eligible participants will receive oral pirtobrutinib or idelalisib every 4 weeks. The trial aims to provide continued access to treatment and follow-up over approximately 5 years.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Eligibility Criteria
Inclusion Criteria
- Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Exclusion Criteria
- This is not applicable to this study
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Mitchell Cancer Institute | 36693 | Mobile | Alabama |
| Arizona Oncology Associates, P.C. - HOPE | 85711 | Tucson | Arizona |
| Cancer Specialists, LLC | 32256 | Jacksonville | Florida |
| University of Maryland | 21201 | Baltimore | Maryland |
| Minnesota Oncology Hematology, P.A. | 55433 | Coon Rapids | Minnesota |
| Memorial Sloan-Kettering Cancer Center (MSKCC) - New York | 10065-6007 | New York | New York |
| Oncology Hematology Care Inc | 45211 | Cincinnati | Ohio |
| Texas Oncology - Paris | 76104 | Fort Worth | Texas |
| US Oncology - Texas Oncology | 78640 | Kyle | Texas |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.